Edwards Lifesciences Corporation Release: The Edwards Lifesciences Fund Supports More Than 150 Organizations in 2010

IRVINE, CA--(Marketwire - November 11, 2010) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today at its Annual Awards Celebration that The Edwards Lifesciences Fund at the Vanguard Charitable Endowment Program plans to grant $4.6 million in 2010 to more than 150 non-profit organizations. This includes $2 million in grants to the University of California, Irvine for the development of The Edwards Lifesciences Center for Advanced Cardiovascular Technology.

"Edwards is dedicated to improving the quality of life around the world by innovating medical technologies that save and protect lives, supporting non-profit organizations through the Fund, and engaging our employees to become involved in their local communities," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "We are proud that the Fund is providing grants to a record number of non-profit organizations this year and that our collective efforts are helping to make a difference."

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," "guidance," or other similar expressions and include, but are not limited to, the Company's expectation for total grants from the Fund in 2010. Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include those and other risks detailed in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2009.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.